Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
KNSA Kiniksa Pharmaceuticals
Post Mkt Price
Do not show
Hide blank lines
Total revenue
32.19M 38.54M 18.75M 12.1M
Operating revenue
-- 32.19M -- 38.54M -- 18.75M -- 12.1M
Cost of revenue
12.47M 9.1M 3.87M 2.77M
Gross profit
19.72M 29.44M 14.88M 9.33M
Operating expense
-12.68% 43.04M 18.25% 186.08M -3.57% 51.01M -7.46% 40M
Selling and administrative expenses
7.85% 22.22M 89.64% 85.95M 46.72% 22.74M 75.94% 20.76M
Research and development costs
-27.42% 20.82M -11.38% 99.3M -26.65% 27.43M -38.78% 19.24M
Other operating expenses
-- -- -- 835K -- 835K -- --
Operating profit
52.68% -23.32M 0.46% -156.64M 31.7% -36.13M 29.04% -30.67M
Net non-operating interest income expense
277.78% 34K -91.45% 97K 156.67% 77K -89.8% 5K
Non-operating interest income
277.78% 34K -91.45% 97K 156.67% 77K -89.8% 5K
Other net income (expense)
Income before tax
52.74% -23.29M -0.2% -156.54M 31.8% -36.05M 28.97% -30.66M
Income tax
816.67% 1.93M -73.12% 1.39M -64.64% 279K -117.69% -118K
Net income
49.05% -25.21M 2.14% -157.92M 32.29% -36.33M 30.32% -30.54M
Net income continuous Operations
49.05% -25.21M 2.14% -157.92M 32.29% -36.33M 30.32% -30.54M
Minority interest income
Net income attributable to the parent company
49.05% -25.21M 2.14% -157.92M 32.29% -36.33M 30.32% -30.54M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
49.05% -25.21M 2.14% -157.92M 32.29% -36.33M 30.32% -30.54M
Basic earnings per share
50% -0.36 11.88% -2.3 32.91% -0.53 33.33% -0.44
Diluted earnings per share
50% -0.36 11.88% -2.3 32.91% -0.53 33.33% -0.44
Dividend per share
Currency Unit
Accounting Standards
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
CEO: Patel, Sanj K.
Market: NASDAQ
Hot List
SymbolLatest price%Chg